The fifth line of investigation is being conducted because of the encouraging results of one of the drugs that the research team in the fourth line of research that the foundation has funded the Center for Cancer Research in Salamanca, led by researcher Dr. Henry of Álava.
Both Dr. de Alava and his research team have asked the Foundation to advance the fifth line of research, so that the Foundation has launched bureaucratic management to advance as soon as possible the next investigation.
The fifth line will begin in January 2012 with the hiring of a second investigator who will focus on drug research.
Studying the value of PARP1 as a therapeutic target in the SE.
PARP1 is overexpressed in more aggressive forms of Ewing sarcoma and maintains a role in the progression of tumor progression and resistance to conventional chemotherapeutic treatments against these tumors, making it a good therapeutic target in monotherapy and in combination with other drugs in the treatment of SE.